The division director of Neuromuscular Medicine & EMG at USF Health provided an overview of the open-label findings from ADAPT-SC, a phase 3 study assessing subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 3 minutes]
Tuan Vu, MD
Advertisement
Articles by Tuan Vu, MD
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy
2
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
3
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
4
Episode 153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
5
